Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy
Crossref DOI link: https://doi.org/10.1186/1471-2407-14-473
Published Online: 2014-06-28
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Machiels, Jean-Pascal H
Licitra, Lisa F
Haddad, Robert I
Tahara, Makoto
Cohen, Ezra EW
License valid from 2014-06-28